ATE521608T1 - Glucokinaseaktivatoren - Google Patents
GlucokinaseaktivatorenInfo
- Publication number
- ATE521608T1 ATE521608T1 AT06826456T AT06826456T ATE521608T1 AT E521608 T1 ATE521608 T1 AT E521608T1 AT 06826456 T AT06826456 T AT 06826456T AT 06826456 T AT06826456 T AT 06826456T AT E521608 T1 ATE521608 T1 AT E521608T1
- Authority
- AT
- Austria
- Prior art keywords
- glucokinase
- glucokinase activators
- underactivity
- diseases
- prevention
- Prior art date
Links
- 102000030595 Glucokinase Human genes 0.000 title abstract 4
- 108010021582 Glucokinase Proteins 0.000 title abstract 4
- 239000012190 activator Substances 0.000 title 1
- 206010011953 Decreased activity Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73203705P | 2005-11-01 | 2005-11-01 | |
| PCT/US2006/041251 WO2007053345A1 (en) | 2005-11-01 | 2006-10-24 | Glucokinase activators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521608T1 true ATE521608T1 (de) | 2011-09-15 |
Family
ID=37685330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06826456T ATE521608T1 (de) | 2005-11-01 | 2006-10-24 | Glucokinaseaktivatoren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8933077B2 (de) |
| EP (1) | EP1948652B1 (de) |
| JP (1) | JP5137207B2 (de) |
| AT (1) | ATE521608T1 (de) |
| AU (1) | AU2006309173B2 (de) |
| CA (1) | CA2628274A1 (de) |
| ES (1) | ES2372540T3 (de) |
| NZ (1) | NZ567858A (de) |
| WO (1) | WO2007053345A1 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1785420A1 (de) * | 2005-11-14 | 2007-05-16 | 4Sc Ag | Thiazolanalogen und ihre Verwendung |
| BRPI0715160A2 (pt) | 2006-08-08 | 2013-06-11 | Sanofi Aventis | imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso |
| CA2681695A1 (en) * | 2007-03-23 | 2008-10-02 | Array Biopharma Inc. | 2-aminopyridine analogs as glucokinase activators |
| WO2009022179A2 (en) * | 2007-08-14 | 2009-02-19 | Astrazeneca Ab | Glucokinase activators in the treatment of osteoarthritis |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| UA101166C2 (ru) | 2007-09-21 | 2013-03-11 | Аррей Биофарма Инк. | Производные пиридин-2-иламино-1,2,4-тиадиазола как активаторы глюкокиназы для лечения сахарного диабета |
| EA201000561A1 (ru) | 2007-10-09 | 2010-10-29 | Мерк Патент Гмбх | Производные пиридина, пригодные в качестве активаторов глюкокиназы |
| JP5364103B2 (ja) | 2007-12-20 | 2013-12-11 | エルジー・ライフ・サイエンシーズ・リミテッド | グルコキナーゼ活性化剤およびそれを活性成分として含有する医薬組成物 |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| WO2010106016A1 (en) * | 2009-03-17 | 2010-09-23 | Glaxo Group Limited | Pyrimidine derivatives used as itk inhibitors |
| WO2011003604A1 (en) * | 2009-07-10 | 2011-01-13 | Bayer Schering Pharma Aktiengesellschaft | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof |
| DK2470552T3 (en) | 2009-08-26 | 2014-02-17 | Sanofi Sa | NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2553086B1 (de) | 2010-03-31 | 2017-04-19 | The Scripps Research Institute | Umprogrammierung von zellen |
| US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683704B1 (de) | 2011-03-08 | 2014-12-17 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2766349B1 (de) | 2011-03-08 | 2016-06-01 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8710050B2 (en) | 2011-03-08 | 2014-04-29 | Sanofi | Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| JPWO2012121314A1 (ja) | 2011-03-09 | 2014-07-17 | 第一三共株式会社 | ジピリジルアミン誘導体 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| HK1210969A1 (en) | 2012-01-20 | 2016-05-13 | 奥克塞拉有限公司 | Substituted heterocyclic compounds for disease treatment |
| US9296735B2 (en) | 2012-05-18 | 2016-03-29 | Amgen Inc. | Method for the preparation of thiadiazoles |
| US11357759B2 (en) | 2017-10-29 | 2022-06-14 | China Medical University | Composition including ADAM9 inhibitor and the use thereof |
| AU2019318209B2 (en) | 2018-08-10 | 2025-09-25 | Diapin Therapeutics, Llc | Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596476B1 (en) * | 1989-12-22 | 2003-07-22 | Abbott Laboratories | Hepatitis C assay |
| US7125875B2 (en) * | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| NZ513639A (en) | 1999-04-15 | 2004-02-27 | Bristol Myers Squibb Co | Cyclic protein tyrosine kinase inhibitors |
| BR0013899A (pt) * | 1999-09-10 | 2003-07-08 | Merck & Co Inc | Composto, composição farmacêutica, processos de tratamento ou prevenção de câncer, de uma doença em que a angiogênese esteja implicada, da vascularização retinal, da retinopatia diabética, da degeneração macular relacionada a idade, de doenças inflamatórias, de uma doença ou condições dependentes da tirosina quinase, de patologias associadas com ossos, e, processos para produzir uma composição farmacêutica, e de reduzir ou prevenir dano tecidual em seguida a um evento isquêmico cerebral |
| EP1345925B1 (de) * | 2000-12-21 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazolverbindungen als proteinkinasehemmer |
| GB0226931D0 (en) * | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| US7629362B2 (en) * | 2003-02-13 | 2009-12-08 | Banyu Pharmaceutical Co., Ltd. | 2-pyridine carboxamide derivatives |
| AU2005223610B2 (en) * | 2004-03-23 | 2008-05-29 | Banyu Pharmaceutical Co., Ltd. | Substituted quinazoline or pyridopyrimidine derivative |
-
2006
- 2006-10-24 AT AT06826456T patent/ATE521608T1/de not_active IP Right Cessation
- 2006-10-24 CA CA002628274A patent/CA2628274A1/en not_active Abandoned
- 2006-10-24 US US12/092,233 patent/US8933077B2/en not_active Expired - Fee Related
- 2006-10-24 WO PCT/US2006/041251 patent/WO2007053345A1/en not_active Ceased
- 2006-10-24 JP JP2008538915A patent/JP5137207B2/ja not_active Expired - Fee Related
- 2006-10-24 EP EP06826456A patent/EP1948652B1/de active Active
- 2006-10-24 NZ NZ567858A patent/NZ567858A/en not_active IP Right Cessation
- 2006-10-24 AU AU2006309173A patent/AU2006309173B2/en not_active Ceased
- 2006-10-24 ES ES06826456T patent/ES2372540T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2372540T3 (es) | 2012-01-23 |
| US20100056530A1 (en) | 2010-03-04 |
| US8933077B2 (en) | 2015-01-13 |
| EP1948652A1 (de) | 2008-07-30 |
| CA2628274A1 (en) | 2007-05-10 |
| EP1948652B1 (de) | 2011-08-24 |
| AU2006309173A1 (en) | 2007-05-10 |
| WO2007053345A1 (en) | 2007-05-10 |
| JP2009513700A (ja) | 2009-04-02 |
| JP5137207B2 (ja) | 2013-02-06 |
| AU2006309173B2 (en) | 2011-08-18 |
| NZ567858A (en) | 2011-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG170775A1 (en) | 2 -aminopyridine analogs as glucokinase activators | |
| TW200740804A (en) | Glucokinase activators | |
| WO2008118718A3 (en) | 2-aminopyridine analogs as glucokinase activators | |
| CR11383A (es) | Derivados piridin-2-il-amino-1,2,4 -tiadiazol como activadores glucoquinasa para el tratamiento de la diabetes mellitus | |
| NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
| TW200745037A (en) | Organic compounds | |
| ATE435015T1 (de) | Substituierte benzazole und ihre verwendung als raf-kinase-hemmer | |
| WO2006091459A3 (en) | Compositions and methods for treating vascular permeability | |
| TW200608979A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| MX2007007409A (es) | Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos. | |
| EA201071089A1 (ru) | Производные хиназолина как модуляторы raf-киназы и способы их применения | |
| GB0402137D0 (en) | Novel compounds | |
| ATE480255T1 (de) | Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen | |
| TNSN06315A1 (en) | Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes | |
| WO2010029089A3 (en) | Combination therapy for the treatment of diabetes and related conditions | |
| NO20092639L (no) | 4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav | |
| GB0402143D0 (en) | Novel compounds | |
| MX2007005590A (es) | Compuestos del inhibidor glicogeno fosforilasa y sus composiciones farmaceuticas. | |
| TW200738724A (en) | Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| TW200714604A (en) | Substituted heterocycles and the uses thereof | |
| MX2010010317A (es) | Compuestos heterociclicos novedosos y usos de los mismos. | |
| ATE552000T1 (de) | Verwendung von isothiocyanat-verbindungen zur behandlung von prostata-erkrankungen und hautkrebs | |
| EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| ATE534649T1 (de) | Imidazothiazole und imidazoxazolderivative als inhibitoren von p38 | |
| WO2008033440A3 (en) | Treatment of hyperproliferative diseases with anthraquinones |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |